Showing results (171-180 of 185) with videos related to

Sort By:
Pageof 19
Blood Advances|October 15, 2020
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AMLJayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2021
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic MalignanciesStephen M Ansell, Michael B Maris, Alexander M Lesokhin, et al.
Blood|January 20, 2019
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403Wendy Stock, Selina M Luger, Anjali S Advani, et al.
Blood Advances|February 11, 2026
ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young AdultsAdam S DuVall, Jennifer McNeer, Matthew C Cheung, et al.
Blood|June 2, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemiaEunice S Wang, Harry P Erba, Amer M Zeidan, et al.
Blood|May 19, 2026
Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi StudyLori Muffly, Noelle V Frey, Gregory W Roloff, et al.
Transplantation and Cellular Therapy|June 27, 2026
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)Rawan G Faramand, Amy Zhang, Gregory W Roloff, et al.
Nature Methods|August 19, 2020
ReDU: a framework to find and reanalyze public mass spectrometry dataAlan K Jarmusch, Mingxun Wang, Christine M Aceves, et al.
Blood Advances|October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemiaYannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Blood|September 15, 2020
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemiaGeoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, et al.
Pageof 19